Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Testing for ALK Fusions and ROS1 Rearrangements in NSCLC

October 25th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.

2024 Regulatory Approvals Across NSCLC Propel the Therapeutic Landscape Forward

October 24th 2024

Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.

ADCs Redefine HER2+ NSCLC Landscape With Potential to Shift to the Frontline Setting

October 23rd 2024

Noman Ashraf, MD, discusses data with T-DXd in HER2-mutated and -overexpressing lung cancer populations and next steps with ADC combination therapies.

Dr Girard on Findings From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC

October 21st 2024

Nicolas Girard, MD, discusses finding from the LUMINOSITY trial in c-Met protein–overexpressing, EGFR wild-type, non–small cell lung cancer.

The OncFive: Top Oncology News and Trends for the Week of 10/13

October 19th 2024

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC

October 18th 2024

Hidehito Horinouchi, MD, PhD, discusses safety data from the ALINA trial of adjuvant alectinib in ALK-positive non–small cell lung cancer.

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

October 16th 2024

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.

Osimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLC

October 16th 2024

Adding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.

FDA Approves Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy

October 15th 2024

The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.

Lurbinectedin/Atezolizumab Combination Improves Survival in ES-SCLC

October 15th 2024

Lurbinectedin plus atezolizumab produced significant OS and PFS benefits as frontline maintenance for extensive-stage small cell lung cancer.

Sunvozertinib Receives Breakthrough Therapy Designation for Treatment-Naive EGFR Exon 20+ NSCLC in China

October 14th 2024

China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.

Chemoimmunotherapy Is at the Forefront of the Perioperative NSCLC Paradigm

October 14th 2024

Combination therapies with neoadjuvant ICIs and chemotherapy followed by an adjuvant ICI are here to stay in resectable non–small cell lung cancer.

Dr Lau on Tarlatamab as Maintenance Therapy in Extensive-Stage SCLC

October 14th 2024

Sally Lau, MD, discusses the addition of tarlatamab to a PD-L1 inhibitor as first-line maintenance therapy for extensive-stage small cell lung cancer.

Dr Wolf on Challenges Conducting Clinical Trials Evaluating Surgery in Mesothelioma

October 11th 2024

Andrea Wolf, MD, MPH, discusses challenges experienced when conducting randomized trials to assess the role of surgery in mesothelioma management.

NMPA Grants Marketing Approval to NGS-Based Companion Diagnostic for Sunvozertinib in EGFR Exon 20+ NSCLC

October 11th 2024

A next generation sequencing–based companion diagnostic has received marketing approval in China for sunvozertinib in EGFR exon 20–positive NSCLC.

Dr Sands on Updated Efficacy Findings With Tarlatamab in Previously Treated SCLC

October 10th 2024

Jacob Sands, MD, discusses updated efficacy findings with tarlatamab treatment in previously treated patients with small cell lung cancer.

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

October 9th 2024

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC

October 9th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail the 11-0 ODAC vote that new trial designs for perioperative regimens in resectable NSCLC should include within-trial assessment of each treatment phase's contribution.

Dr Garassino on the Potential Use of a TROP2 Biomarker to Predict Outcomes With Dato-DXd in NSCLC

October 8th 2024

Marina Chiara Garassino, MD, discusses the predictive utility of a TROP2 computational pathway biomarker for outcomes with Dato-DXd in pretreated NSCLC.

Dr Girard on the Safety of Nivolumab/Relatlimab/Chemotherapy in Untreated NSCLC

October 8th 2024

Nicolas Girard, MD, discusses the safety of nivolumab plus relatlimab and chemotherapy for untreated stage IV or recurrent non–small cell lung cancer.